Prolymphocytic Leukemia Overview
Learn About Prolymphocytic Leukemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
The University Of Chicago Medical Center
Justin Kline is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Kline and is rated as a Distinguished provider by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kline is currently accepting new patients.
Advocate Health And Hospitals Corporation
Sylvia Falls is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Falls and is rated as an Experienced provider by MediFind in the treatment of Prolymphocytic Leukemia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Adenocarcinoma, and Colorectal Cancer. Dr. Falls is currently accepting new patients.
University Of Chicago
Shayan Rayani is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Rayani and is rated as an Advanced provider by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast. Dr. Rayani is currently accepting new patients.
Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Summary: This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolat...